SRC and neoplasm: Several in vitro and in vivo studies have demonstrated potential anti-tumour and anti-osteoclast activity of the Src inhibitors, dasatinib (BMS-354825, Bristol-Myers-Squibb) and saracatinib (AZD-0530, AstraZeneca) (Nam et al. 2005; Chang et al. 2008; Park et al. 2008; Vandyke et al. 2009; Brownlow et al. 2009; Araujo et al. 2009; Koreckij et al. 2009).